Anti-VEGF Injection

BARCELONA, Spain — A subgroup analysis of the DAVIO 2 trial showed that eyes implanted with the EYP-1901 intravitreal insert maintained stable visual acuity with strong anatomic control over 8 months, according to a presenter.

BARCELONA, Spain — In this Healio Video Perspective from the Euretina meeting, Francesco Boscia, MD, discusses the role of new anti-VEGF agents in the treatment of pigment epithelial detachment.

Roy Rubinfeld’s description of his experience as a clinician innovator is typical of those who attempt to bring a new drug, device or diagnostic from the bench to the bedside.

Eluminex Biosciences has dosed the first patient in the phase 1b LOTUS trial, which will evaluate three dose levels of the trispecific fusion antibody EB-105 in patients with diabetic macular edema.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Charles Semba, MD, chief medical officer of Eluminex Biosciences, discusses a trispecific antibody for refractory diabetic macular edema.

The current prior authorization process required for anti-VEGF medications leads to treatment delays, increased health care costs due to administrative burdens and potentially worse visual outcomes.

SEATTLE — Receiving travel support may help patients with age-related macular degeneration undergo more injections, regardless of the distance needed to travel for treatment, according to research presented at the Association for Research in Vision and Ophthalmology meeting.

SEATTLE — In this Healio Video Perspective from the ARVO meeting, Jennifer I. Lim, MD, discusses anti-VEGF therapy for the treatment of proliferative sickle cell retinopathy.

RetinalGeniX has contracted with Medsan to provide diagnostic testing for a study on personalizing medical evaluations for patients with wet age-related macular degeneration.